Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats (Q44575160)

4 December 2017

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats (English)

1 reference

4 December 2017

pulmonary hypertension

1 reference

3

1 reference

4 December 2017

12

1 reference

4 December 2017

13

1 reference

4 December 2017

Norbert Weissmann

8

0 references

Ralph T Schermuly

object named as

Ralph T Schermuly

1

0 references

Ghazwan Butrous

5

object named as

Ghazwan Butrous

1 reference

4 December 2017

10

Andreas Guenther

1 reference

4 December 2017

11

Dieter Walmrath

1 reference

4 December 2017

6

Leander Ermert

1 reference

4 December 2017

7

Monika Ermert

1 reference

4 December 2017

Klaus P Kreisselmeier

2

1 reference

4 December 2017

Hüseyin Yilmaz

4

1 reference

4 December 2017

Frank Rose

9

1 reference

4 December 2017

language of work or name

English

0 references

publication date

4 September 2003

1 reference

American Journal of Respiratory and Critical Care Medicine

4 December 2017

1 reference

4 December 2017

169

1 reference

4 December 2017

1

1 reference

4 December 2017

39-45

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

4 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Activation and pulmonary toxicity of pyrrolizidine alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Mechanisms and pathology of monocrotaline pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200302-282OC

10.1164/RCCM.200302-282OC

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference